Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 19/20 | 0.44 |
| ▸ | BACE2 | Q9Y5Z0 | 10/20 | 0.40 |
| ▸ | APP | P05067 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10325730 | 0.89 | BACE1 (0.42) | BACE1BACE2APPCYP3A4CYP2D6 | |
| SCHEMBL10325197 | 0.89 | BACE1 (0.44) | BACE1 | |
| SCHEMBL362791 | 0.86 | BACE1 (0.49) | BACE1BACE2APPCYP3A4CYP2D6 | |
| SCHEMBL16479732 | 0.81 | BACE1 (0.59) | BACE1BACE2 | |
| SCHEMBL16479733 | 0.80 | BACE1 (0.55) | BACE1BACE2 | |
| SCHEMBL14861981 | 0.79 | BACE1 (0.46) | BACE1BACE2APP | |
| SCHEMBL10325832 | 0.78 | BACE1 (0.41) | BACE1BACE2 | |
| SCHEMBL16479744 | 0.77 | BACE2 (0.63) | BACE1BACE2 | |
| SCHEMBL10325306 | 0.77 | BACE1 (0.74) | BACE1BACE2APPCYP3A4CYP2D6 | |
| SCHEMBL10325378 | 0.76 | BACE1 (0.56) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2663559-B1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-07-01 | — | — | EP | disclosed |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | disclosed |
| EP-2663308-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | disclosed |
| EP-2663559-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-20130281449-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| WO-2012095463-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281449-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | GRIK5, OTC, GRIN2C | BACE1 74/4885BACE2 214/4885APP 148/4885 |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | BACE2, BACE1, IAPP | BACE1 2/4885BACE2 1/4885APP 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.